Joon Oh Park

Active 2003–2025

Also published as
Joon-Oh Park
131
Papers
27,486
Citations
76
h-index
124
i10-index

Citations

Citations per year for Joon Oh Park1979: 1 citations1994: 1 citations2001: 1 citations2002: 1 citations2003: 3 citations2004: 7 citations2005: 14 citations2006: 25 citations2007: 38 citations2008: 128 citations2009: 114 citations2010: 128 citations2011: 135 citations2012: 139 citations2013: 161 citations2014: 210 citations2015: 222 citations2016: 191 citations2017: 226 citations2018: 228 citations2019: 894 citations2020: 1,163 citations2021: 1,317 citations2022: 1,092 citations2023: 806 citations2024: 1,413 citations2025: 849 citations2026: 24 citations1980–1993: no citations, so these years are not shown1995–2000: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,197 citing papers, 23.9% of this breakdownChina: 2,147 citing papers, 16% of this breakdownJapan: 799 citing papers, 6% of this breakdownItaly: 787 citing papers, 5.9% of this breakdownGermany: 672 citing papers, 5% of this breakdownSouth Korea: 672 citing papers, 5% of this breakdownUnited Kingdom: 665 citing papers, 5% of this breakdownFrance: 481 citing papers, 3.6% of this breakdownSpain: 454 citing papers, 3.4% of this breakdownCanada: 319 citing papers, 2.4% of this breakdownNetherlands: 287 citing papers, 2.1% of this breakdownAustralia: 222 citing papers, 1.7% of this breakdown
0%23.9%Other 20%

Fields

  • Medicine71.7%
  • Biochemistry, Genetics and Molecular Biology21.6%
  • Immunology and Microbiology2.9%
  • Materials Science0.8%
  • Computer Science0.7%
  • Neuroscience0.7%
  • Other1.6%

Topics

  • Pancreatic and Hepatic Oncology Research6.9%
  • Cancer Immunotherapy and Biomarkers4.9%
  • Cancer Genomics and Diagnostics4.4%
  • Lung Cancer Treatments and Mutations4.4%
  • Gastric Cancer Management and Outcomes3.8%
  • Cholangiocarcinoma and Gallbladder Cancer Studies3.6%
  • Other72%

Coauthors

All papers

Open in search
  1. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Yuxian Bai, Olga Barajas, Susan E. Bates, Stephen Begbie, Irit Ben‐Aharon, Nina Beri, Marie‐Luise Berres, Jean‐Frédéric Blanc, Ivan Borbath, Robert Bordonaro, Mohamed Bouattour, Giovanni Brandi, Adam M. Burgoyne, Kritiya Butthongkomvong, Marcos Pedro Guedes Camandaroba, Ke Cao, Marcela Carballido, Marcela Carballido, Jen‐Shi Chen, Ming‐Huang Chen, Ming-Huang Chen, Ashley Cheng, Tai‐Jan Chiu, Hye Jin Choi, Hong Jae Chon, Joëlle Collignon, Antonio Cubillo Gracián, S. Lindsey Davis, Ricardo Saraiva de Carvalho, D.J.A. de Groot, Anne Demols, Judith de Vos, Maria Diab, Jacob C. Easaw, Martin Eatock, Julien Edeline, Rawad Elias, Fredericus Eskens, Alfredo Falcone, Plinio Fernández, Richard S. Finn, Fábio Franke, Masayuki Furukawa, Junji Furuse, Olumide B. Gbolahan, Karen Geboes, Keri-Lee Geneser, Zhimin Geng, Ravit Geva, Roopinder Gillmore, Thorsten Oliver Goetze, Hongfeng Gou, Julieta Grasselli, Shanzhi Gu, Mahmut Gümüş, Nadia Haj Mohammad, Chunyi Hao, Hakan Harputluoğlu, Hassan Hatoum, Volker Heinemann, Wang Kwong Ho, Chiun Hsu, Ayala Hubert, Jun‐Eul Hwang, Mevlüde İnanç, Soledad Iseas, Vaishnavi Jeyasingam, Paula Jiménez Fonseca, Warren Joubert, Jitlada Juengsamarn and 116 more - The Lancet 2023 cited by 1,025

  2. Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , - Nature Medicine 2018 cited by 1,717

  3. Maintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic Cancer

    Authors: , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2019 cited by 2,213

  4. BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - Nature Medicine 2020 cited by 533

  5. MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

    Authors: , , , , , , , , , , , , , , , , , , - Science 2007 cited by 4,485

  6. Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2020 cited by 446

  7. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jen‐Shi Chen, Yeu‐Chin Chen, Hye Jin Choi, Ik Joo Chung, Vincent Chung, Tibor Csőszi, Antonio Cubillo, Linda C. DeMarco, Maike de Wit, Tomislav Dragovich, W. Jeff Edenfield, Luis Fein, Fábio Franke, Martin Fuchs, Vega Gonzales-Cruz, Alberto Gozza, Rivera Herrero Fernando, Rosario Vincenzo Iaffaioli, Jitka Jakesova, Zsuzsanna Kahán, Misagh Karimi, Jun Suk Kim, Ernesto Korbenfeld, István Láng, Fa-Chyi Lee, Kuan‐Der Lee, Lara Lipton, Wen Wee, László Mangel, Raul Mena, Daniel H. Palmer, Shubham Pant, Joon Oh Park, Paolo Piacentini, Uwe Pelzer, Javier Gállego, Cooray Prasad, Kun‐Ming Rau, Jean‐Luc Raoul, Donald Richards, Paul J. Ross, Luís Alberto Schlittler, Martin Šmakal, V. Stahalova, Cora N. Sternberg, Thomas Seufferlein, Niall C. Tebbutt, J. Vinholes, Raymond Wadlow, Milkos Wenczl, Mark Wong - The Lancet 2015 cited by 1,200

  8. Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Eric X. Chen, Ying Cheng, Antonio Cubillo Gracián, Laëtitia Dahan, Filippo de Braud, Elisabetta Fenocchio, Olumide Gbolohon, Roopinder Gillmore, Marine Jary, Milind Javle, Yixing Jiang, Jung Hun Kang, Gentry George King, Madappa N. Kundranda, Laura Layos, Daneng Li, Tingbo Liang, Sara Lonardi, Omkar Marathe, Sebastián Mondaca, Andrés J. Muñoz Martín, Joon Oh Park, Roberto Pazo-Cid, Paula Ribera Fernandez, Lorenza Rimassa, Rosa Alonso, Saeed Sadeghi, Aaron J. Scott, Benjamin Tan, David Tougeron, Qiang Yan, Xiaoyu Yin, Haitao Zhao - The Lancet Oncology 2023 cited by 247

  9. An Exosome-based Transcriptomic Signature for Noninvasive, Early Detection of Patients With Pancreatic Ductal Adenocarcinoma: A Multicenter Cohort Study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Gastroenterology 2022 cited by 162

  10. Single-cell transcriptome analysis of tumor and stromal compartments of pancreatic ductal adenocarcinoma primary tumors and metastatic lesions

    Authors: , , , , , , , , , , , , , , , - Genome Medicine 2020 cited by 342

  11. Futibatinib, an Irreversible FGFR1–4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF / FGFR Aberrations: A Phase I Dose-Expansion Study

    Authors: , , , , , , , , , , , , - Cancer Discovery 2021 cited by 248

  12. Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer

    Authors: , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2022 cited by 225

  13. Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Roopinder Gillmore, Vineet Gupta, Farshid Dayyani, Joon Oh Park, Gary L. Buchschacher, Felipe Rey, Hyosung Kim, Julie Wang, Claire Morgan, Nana Rokutanda, Magdalena Żotkiewicz, Arndt Vogel, Juan W. Valle - ˜The œLancet. Gastroenterology & hepatology 2024 cited by 254

  14. Adjuvant nab -Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Michele Reni, Richard A. Epstein, Paul L. Vasey, Jeremy Shapiro, Matthew Burge, Yu Jo Chua, Marion Harris, Nick Pavlakis, Niall C. Tebbutt, Gerald W. Prager, Christian Dittrich, Friedrich Längle, Kathrin Philipp‐Abbrederis, Richard Greil, Herbert Stöger, Michael Girschikofsky, Thomas Kuehr, Jean–Luc Van Laethem, Stéphanie Laurent, Neesha C. Dhani, Yoo Joung Ko, Scot Dowden, Petr Kavan, Mustapha Édouard Tehfe, Eugen Kubala, Milan Kohoutek, Per Pfeiffer, Mette Yilmaz, Vibeke K. Parner, Tapio Salminen, Leena‐Maija Soveri, Eija Korkeila, Pia Österlund, Julien Taı̈eb, David Tougeron, Pascal Artru, François‐Xavier Caroli‐Bosc, Rosine Guimbaud, Antony Turpin, Thomas Walter, Jean‐Baptiste Bachet, Volker Kunzmann, Florian Kreth, Andreas De Block, Marino Venerito, Helmut Oettle, Meinolf Karthaus, Jörg Trojan, Gunnar Folprecht, Markus M. Lerch, Frank Kullmann, Marcel Reiser, Volker Heinemann, Marcus‐Alexander Wörns, H. Schulz, Benjamin Garlipp, Thomas Yau, Lam Stephen Chan, Balázs Juhász, László Landherr, Tamás Pintér, G. Bodoky, Zsuzsanna Kahán, Raymond McDermott, Derek G. Power, Luca Gianni, Salvatore Siena, Michèle Milella, Alfredo Falcone, Rossana Berardi and 87 more - Journal of Clinical Oncology 2022 cited by 132

  15. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2015 cited by 845

  16. Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer

    Authors: , , , , , , , , , , , , , , , , , , , - Annals of Surgery 2018 cited by 679

  17. Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2–Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC—A Randomized Phase III Trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2015 cited by 621

  18. Claudin 18.2 expression in various tumor types and its role as a potential target in advanced gastric cancer

    Authors: , , , , , , , , , - Translational Cancer Research 2020 cited by 93

  19. Tumor Genomic Profiling Guides Patients with Metastatic Gastric Cancer to Targeted Treatment: The VIKTORY Umbrella Trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jung Yong Hong, Se Hoon Park, Joon Oh Park, Young Suk Park, Ho Yeong Lim, AmirAli Talasaz, Simon J. Hollingsworth, Kyoung‐Mee Kim, Won Ki Kang - Cancer Discovery 2019 cited by 234

  20. A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas

    Authors: , , , , , , , , , , - European Journal of Cancer 2014 cited by 363

  21. Patient-derived exosomes facilitate therapeutic targeting of oncogenic MET in advanced gastric cancer

    Authors: , , , , , , , , , , - Science Advances 2023 cited by 43

  22. Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Maria de Miguel, Maitri Kalra, Do-Youn Oh, Joon Oh Park, Sophie Postel-Vinay, Sun Young Rha, Taroh Satoh, Iben Spanggaard, Flavia Michelini, Ann Smith, Karime Kalil Machado, Cristina Saura - The Lancet Oncology 2024 cited by 101

  23. Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Matthew Burge, Sumitra Ananda, Muhammad A. Khattak, Bruce Colwell, Félix Couture, Brandon M. Meyers, Kathryn Towns, Michael B. Sawyer, Lucas Sidéris, Rui‐Hua Xu, Wei Wang, Hongming Pan, Per Pfeiffer, Lars Henrik Jensen, Camilla Qvortrup, Sebastian Stintzing, Dirk Arnold, Sylvie Lorenzen, Stefan Kubicka, Reinhard Depenbusch, Maria Passhak, Ravit Geva, Ayala Hubert, Einat Shacham‐Shmueli, Gleb Kornev, Akihito Kawazoe, Toshiki Masuishi, Atsuo Takashima, Hiroki Hara, Hisato Kawakami, Nozomu Machida, Kentaro Yamazaki, Hisateru Yasui, Akihito Tsuji, Taito Esaki, Kensei Yamaguchi, Tae‐You Kim, Joong Bae Ahn, Myung Ah Lee, Tae Won Kim, Joon Oh Park, Soo Hyun Lee, Р. В. Орлова, V. O. Sarzhevskiy, Marina Sekacheva, S. Tjulandin, Oksana Shirokova, A.I. Iskhakova Iskhakova, A. A. Lebedinets, Paula Jiménez Fonseca, F. Rivera Herrero, Elena Elez Fernandez, Pilar Alfonso, M.J. Gómez Reina, Kun‐Huei Yeh, Hao‐Wei Teng, Tsai Sheng Yang, Hwei‐Ming Wang, Yu‐Min Yeh, Mustafa Özgüroğlu, Mahmut Gumus, Şuayib Yalçın, Bülent Erdoğan, Umut Demırcı, Pınar Gürsoy, Hakan Harputluoğlu, Atakan Demir, Kai‐Keen Shiu, Ewan Brown, Paul J. Ross and 13 more - Journal of Clinical Oncology 2024 cited by 77

  24. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial

    Authors: , , , , , , , , , , , , , , , - The Lancet Oncology 2013 cited by 838